Comments on proposed changes to the Personal Responsibility and Work Opportunity Reconciliation Act of 1996.
Comments regarding Medicare Drug Price Negotiation Program draft guidance.
A fact sheet regarding upcoming Medicare Cost Smoothing.
Comments on proposed changes to the Medicare Advantage and Prescription Drug Plans Bid Pricing Tool.
Comments regarding Medicare Part D 2024-2025 Plans.
Analysis of the ongoing regulatory and public health effects of the overturning of Chevron Deference and the Braidwood SCOTUS ruling.
Comments on projected Medicaid coverage losses under the “One Big Beautiful Bill”
Comments to the HHS Office of Intergovernmental and External Affairs regarding implementation considerations for Medicare Part D and the Inflation Reduction Act (IRA) for people aging with HIV (PAWH).
Comments to the leadership of the US Senate Health, Education, Labor, and Pensions (HELP) Committee regarding proposed reforms to the Pharmacy Benefit Manager (PBM) system.
Comments on the Oregon Prescription Drug Affordability Board’s affordability review of Odefsey.
Co-signed letter to the leadership of the US Senate regarding the introduced Pioneering Antimicrobial Subscriptions To End Upsurging Resistance (PASTEUR) Act.